Pharos iBio

[On Demand]
Pharos iBio is a clinical stage biotech company that develops novel drug for rare and refractory diseases using AI(Artificial Intelligence)-based new drug discovery platform, “Chemiverse”. The Chemiverse platform is Pharos iBio’s proprietary platform using big data, AI-based 3D protein structure and inter-molecular analysis. Using the optimal compound discovered from the Chemiverse, Pharos iBio accelerate the drug development through Open Innovation program. PHI-101 has been derived from Pharos iBio’s drug discovery and development platform making the drug of optimization and exploring new indications. The global Phase I clinical trials of PHI-101 for AML are undergoing, and Phase 1 clinical trials for ovarian cancers are undergoing in South Korea.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Pharos iBio